title: SULFs in human neoplasia: implication as progression and prognosis factors.
abstract: BACKGROUND
  The sulfation pattern of heparan sulfate chains influences signaling events mediated by heparan sulfate proteoglycans located on cell surface. SULF1 and SULF2 are two endosulfatases able to cleave specific 6-O sulfate groups within the heparan chains. Their action can modulate signaling processes, many of which with key relevance for cancer development and expansion. SULF1 has been associated with tumor suppressor effects in various models of cancer, whereas SULF2 dysregulation was in relation with protumorigenic actions. However, other observations argue for contradictory effects of these sulfatases in cancer, suggesting the complexity of their action in the tumor microenvironment.
  
  
  METHODS
  We compared the expression of the genes encoding SULF1, SULF2 and heparan sulfate proteoglycans in a large panel of cancer samples to their normal tissue counterparts using publicly available gene expression data, including the data obtained from two cohorts of newly-diagnosed multiple myeloma patients, the Oncomine Cancer Microarray database, the Amazonia data base and the ITTACA database. We also analysed prognosis data in relation with these databases.
  
  
  RESULTS
  We demonstrated that SULF2 expression in primary multiple myeloma cells was associated with a poor prognosis in two independent large cohorts of patients. It remained an independent predictor when considered together with conventional multiple myeloma prognosis factors. Besides, we observed an over-representation of SULF2 gene expression in skin cancer, colorectal carcinoma, testicular teratoma and liver cancer compared to their normal tissue counterpart. We found that SULF2 was significantly over-expressed in high grade uveal melanoma compared to low grade and in patients presenting colorectal carcinoma compared to benign colon adenoma.We observed that, in addition to previous observations, SULF1 gene expression was increased in T prolymphocytic leukemia, acute myeloid leukemia and in renal carcinoma compared to corresponding normal tissues. Furthermore, we found that high SULF1 expression was associated with a poor prognosis in lung adenocarcinoma.Finally, SULF1 and SULF2 were simultaneously overexpressed in 6 cancer types: brain, breast, head and neck, renal, skin and testicular cancers.
  
  
  CONCLUSIONS
  SULF1 and SULF2 are overexpressed in various human cancer types and can be associated to progression and prognosis. Targeting SULF1 and/or SULF2 could be interesting strategies to develop novel cancer therapies.
authors: INSERM U847, Institut de Recherche en Biothérapie, CHRU de Montpellier, France.
authors: Caroline
authors: C
authors: Bret
authors: Jérôme
authors: J
authors: Moreaux
authors: Jean-François
authors: JF
authors: Schved
authors: Dirk
authors: D
authors: Hose
authors: Bernard
authors: B
authors: Klein
references: Blood. 2006 Dec 15;108(13):4194-7
references: 16946299
references: Int J Oncol. 2007 Dec;31(6):1491-500
references: 17982676
references: Connect Tissue Res. 2008;49(3):207-10
references: 18661344
references: Dev Biol. 2007 Nov 15;311(2):464-77
references: 17920055
references: Clin Cancer Res. 2007 Aug 15;13(16):4740-9
references: 17699851
references: Mol Cancer. 2010 May 20;9:115
references: 20487546
references: Int J Cancer. 2009 Feb 1;124(3):739-44
references: 19006069
references: PLoS One. 2007 Jun 27;2(6):e575
references: 17593974
references: Oncogene. 2007 Jul 26;26(34):4969-78
references: 17310998
references: Cancer Res. 2004 Oct 15;64(20):7205-9
references: 15492234
references: Nat Genet. 2004 Mar;36(3):257-63
references: 14770183
references: J Clin Oncol. 2008 Oct 10;26(29):4798-805
references: 18591550
references: Haematologica. 2011 Jan;96(1):87-95
references: 20884712
references: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
references: 11707567
references: Expert Opin Ther Targets. 2010 Sep;14(9):935-49
references: 20629619
references: Nucleic Acids Res. 2006 Jan 1;34(Database issue):D613-6
references: 16381943
references: J Clin Pathol. 2006 Oct;59(10):1052-8
references: 16603650
references: Oncogene. 2005 Jun 2;24(24):3896-905
references: 15750623
references: Development. 2007 Sep;134(18):3327-38
references: 17720696
references: J Biol Chem. 2002 Dec 20;277(51):49175-85
references: 12368295
references: Hepatology. 2007 Apr;45(4):938-47
references: 17393520
references: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references: 12829800
references: Cancer Res. 2005 Jul 1;65(13):5588-98
references: 15994931
references: J Biol Chem. 2005 Dec 2;280(48):40066-73
references: 16192265
references: Gastroenterology. 2006 Jun;130(7):2130-44
references: 16762634
references: PLoS One. 2007 Apr 25;2(4):e392
references: 17460759
references: Cancer Res. 2009 Jun 1;69(11):4843-50
references: 19487294
references: Gastroenterology. 2004 Jan;126(1):231-48
references: 14699503
references: Orv Hetil. 2008 Jul 20;149(29):1373-7
references: 18617470
references: J Biol Chem. 2008 Oct 10;283(41):27724-27735
references: 18687675
references: Curr Opin Chem Biol. 2000 Dec;4(6):626-31
references: 11102866
references: Future Oncol. 2008 Dec;4(6):803-14
references: 19086847
references: Blood. 2009 May 7;113(19):4614-26
references: 19228610
references: BMC Med Genomics. 2008 Apr 28;1:13
references: 18442402
references: Neoplasia. 2005 Nov;7(11):1001-10
references: 16331886
references: J Cell Physiol. 2007 Jan;210(1):111-21
references: 17044071
references: Leukemia. 2007 Oct;21(10):2153-63
references: 17713554
references: Exp Cell Res. 2009 Oct 1;315(16):2752-64
references: 19577565
references: Blood. 2006 Sep 15;108(6):2020-8
references: 16728703
references: Br J Haematol. 2009 May;145(3):350-68
references: 19298595
references: J Biol Chem. 2007 May 11;282(19):14413-20
references: 17363371
references: Blood. 2007 Mar 15;109(6):2276-84
references: 17105813
references: Biochem J. 2010 Mar 15;427(1):1-17
references: 20226003
references: Cancer Res. 2006 Jun 15;66(12):6025-32
references: 16778174
references: J Hepatol. 2009 Jun;50(6):1112-21
references: 19376607
references: J Cell Mol Med. 2009 Nov-Dec;13(11-12):4505-21
references: 20394677
references: Stem Cells. 2007 Apr;25(4):961-73
references: 17204602
references: Hepatology. 2008 Apr;47(4):1211-22
references: 18318435
references: Lancet. 2003 May 10;361(9369):1590-6
references: 12747878
references: Oncogene. 2004 Feb 19;23(7):1439-47
references: 14973553
references: Neoplasia. 2004 Jan-Feb;6(1):1-6
references: 15068665
references: Oncogene. 2010 Feb 4;29(5):635-46
references: 19855436
references: Cancer Res. 2009 Feb 15;69(4):1368-74
references: 19190338
references: J Biol Chem. 2003 Jun 20;278(25):23107-17
references: 12686563